Related Experiment Videos
The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics
Daniella I Zheleva1, David P Lane, Peter M Fischer
1Cyclacel Limited, James Lindsay Place, Dundee, Scotland, UK.
Abstract:
The tumour suppressor p53 is at the centre of a network of regulatory pathways that guard over the continued integrity of the living cell and its progeny after exposure to different forms of stress, particularly those capable of inducing DNA damage. Tumour cells very frequently circumvent this control by disabling the function of p53, or other proteins in the p53 network, through mutation. Here we review the different therapeutic strategies that have been adopted to exploit common neoplastic aberrations in the p53 pathways. We emphasise in particular those approaches where modulation with pharmaceutical agents has already shown some promise, including pharmacological rescue of mutant p53, modulation of the protein-protein interaction between p53 and one of its negative regulators, Mdm2, as well as interference with downstream targets.
Insights
The tumor suppressor p53 pathway is crucial for cellular integrity. Therapeutic strategies targeting p53 pathway aberrations, including mutant p53 rescue and Mdm2 modulation, show promise for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The p53 pathway is a critical cellular defense mechanism against DNA damage and stress.
- Cancer cells frequently inactivate the p53 pathway through mutations to evade apoptosis.
- Aberrations in the p53 network are common in various tumor types.
Purpose of the Study:
- To review therapeutic strategies targeting neoplastic aberrations in the p53 pathway.
- To highlight promising pharmaceutical approaches for cancer treatment.
- To discuss the exploitation of p53 pathway dysregulation in oncology.
Main Methods:
- Review of existing literature on p53 pathway therapeutics.
- Emphasis on pharmaceutical modulation of p53 and its regulators.
- Analysis of strategies targeting mutant p53 and downstream effectors.
Main Results:
- Several therapeutic strategies targeting p53 pathway defects have been developed.
- Pharmacological rescue of mutant p53 shows potential therapeutic benefit.
- Modulation of p53-Mdm2 interaction and downstream targets are promising avenues.
Conclusions:
- Targeting the p53 pathway offers a viable strategy for cancer therapy.
- Pharmaceutical interventions modulating p53 function and its network are advancing.
- Exploiting p53 pathway aberrations presents opportunities for novel cancer treatments.